The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently ...

The biosimilar was not approved for other forms ... at least 3% of adults reported headache, injection site reactions, arthralgia, upper abdominal pain, and dizziness. At least 3% of food allergy ...

South Korea’s Celltrion (Kosdaq: 068270) has announced the US launch of Steqeyma (ustekinumab-stba), a biosimilar to Stelara ...

Celltrion today announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), following ...

Celltrion has launched Steqeyma (ustekinumab-stba), its biosimilar of Stelara (ustekinumab), at list price at an 85% discount ...

Teva Pharmaceuticals and Alvotech have announced the US launch of the Selarsdi (ustekinumab-aekn) injection, a biosimilar to Johnson & Johnson’s Stelara (ustekinumab). The product is indicated ...

The US Food and Drug Administration approved the first-ever rapid-acting insulin for reducing blood sugar levels. It calls ...

Celltrion’s Omlyclo is interchangeable with Xolair to treat the same conditions: asthma, chronic rhinosinusitis, food allergy ...

Omlyclo is the first interchangeable biosimilar to omalizumab (Xolair ... Adverse events associated with Omlyclo include injection site reactions, fever, headache, dizziness and arthralgia.

Celltrion today announced the U.S. launch of STEQEYMA��(ustekinumab-stba), a biosimilar to STELARA� (ustekinumab), following approval by the U.S. Food and Drug Administration (FDA) in December 2024.